Literature DB >> 23921461

Dual diagnosis screening interview to identify psychiatric comorbidity in substance users: development and validation of a brief instrument.

Joan Ignasi Mestre-Pintó1, Antònia Domingo-Salvany, Rocío Martín-Santos, Marta Torrens.   

Abstract

AIM: The objective of this study was to develop and validate a brief tool, the Dual Diagnosis Screening Instrument (DDSI), to screen psychiatric disorders in substance users in treatment and nontreatment-seeking samples.
METHODS: A total of 827 substance users (66.5% male, mean age 28.6±9.9 years) recruited in treatment (in- and outpatient) and nontreatment (substance user volunteers in university research studies) settings were assessed by trained interviewers using the DDSI and the Psychiatric Research Interview for Substance and Mental Disorders (PRISM) as the criterion standard. Both instruments were administered blind to the results of the other. Disorders obtained with the DDSI were compared to lifetime diagnoses obtained with the PRISM. Sensitivity, specificity, negative, and positive predictive values were estimated. Also test-retest reliability of the DDSI was assessed.
RESULTS: The DDSI showed a high sensitivity (≥80%) for identifying lifetime depression, mania, psychosis, panic, social phobia, and specific phobia disorders. Specificity was ≥82% for those diagnoses. Test-retest κ showed excellent agreement (range 81-95%). The mean duration of the DDSI administration was 16.8±2.5 min.
CONCLUSION: The DDSI is a valid and easy-to-administer screening tool to detect possible psychiatric comorbidity among substance users.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23921461     DOI: 10.1159/000351519

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  10 in total

1.  Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population.

Authors:  Deborah S Hasin; Dvora Shmulewitz; Malka Stohl; Eliana Greenstein; Christina Aivadyan; Kara Morita; Tulshi Saha; Efrat Aharonovich; Jeesun Jung; Haitao Zhang; Edward V Nunes; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2015-04-06       Impact factor: 4.492

2.  The Alcohol Use Disorder and Associated Disabilities Interview Schedule-5 (AUDADIS-5): procedural validity of substance use disorders modules through clinical re-appraisal in a general population sample.

Authors:  Deborah S Hasin; Eliana Greenstein; Christina Aivadyan; Malki Stohl; Efrat Aharonovich; Tulshi Saha; Rise Goldstein; Edward V Nunes; Jeesun Jung; Haitao Zhang; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

3.  Feasibility of an Extensive Strategy for Adult Diagnosis of Attention Deficit Hyperactivity Disorder Among Patients Suffering From Substance Use Disorders.

Authors:  Norman Therribout; Emily Karsinti; Alix Morel; Alexandra Dereux; Florence Vorspan; Lucia Romo; Romain Icick
Journal:  Front Psychiatry       Date:  2022-06-28       Impact factor: 5.435

4.  Preventive Medication Patterns in Bipolar Disorder and Their Relationship With Comorbid Substance Use Disorders in a Cross-National Observational Study.

Authors:  Romain Icick; Ingrid Melle; Bruno Etain; Margrethe Collier Høegh; Sébastien Gard; Sofie R Aminoff; Marion Leboyer; Ole A Andreassen; Raoul Belzeaux; Chantal Henry; Thomas D Bjella; Jean-Pierre Kahn; Nils Eiel Steen; Frank Bellivier; Trine Vik Lagerberg
Journal:  Front Psychiatry       Date:  2022-05-03       Impact factor: 5.435

5.  Evaluation of plasma cytokines in patients with cocaine use disorders in abstinence identifies transforming growth factor alpha (TGFα) as a potential biomarker of consumption and dual diagnosis.

Authors:  Rosa Maza-Quiroga; Nuria García-Marchena; Pablo Romero-Sanchiz; Pedro Araos; Vicente Barrios; María Pedraz; Antonia Serrano; Raquel Nogueira-Arjona; Juan Jesus Ruiz; Maribel Soria; Rafael Campos; Julie Ann Chowen; Jesus Argente; Marta Torrens; Meritxell López-Gallardo; Eva María Marco; Fernando Rodríguez de Fonseca; Francisco Javier Pavón
Journal:  PeerJ       Date:  2017-10-12       Impact factor: 2.984

6.  Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany.

Authors:  Hanna Dauber; Barbara Braun; Tim Pfeiffer-Gerschel; Ludwig Kraus; Oliver Pogarell
Journal:  Int J Ment Health Addict       Date:  2017-07-11       Impact factor: 3.836

7.  Risk-taking and fairness among cocaine-dependent patients in dual diagnoses: Schizophrenia and Anti-Social Personality Disorder.

Authors:  Gerardo Sabater-Grande; Gonzalo Haro; Aurora García-Gallego; Nikolaos Georgantzís; Noemí Herranz-Zarzoso; Abel Baquero
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

8.  Brazilian cross-cultural adaptation and validation of the List of Threatening Events Questionnaire (LTE-Q).

Authors:  Patrícia B de Abreu; Hugo Cogo-Moreira; Regina A Pose; Ronaldo Laranjeira; Raul Caetano; Carolina M Gaya; Clarice S Madruga
Journal:  Braz J Psychiatry       Date:  2017-05-22       Impact factor: 2.697

9.  Dual Disorders in the Consultation Liaison Addiction Service: Gender Perspective and Quality of Life.

Authors:  Teresa Ferrer-Farré; Fernando Dinamarca; Joan Ignasi Mestre-Pintó; Francina Fonseca; Marta Torrens
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

10.  Lifetime Dual Disorder Screening and Treatment Retention: A Pilot Cohort Study.

Authors:  Beatriz Puértolas-Gracia; María Gabriela Barbaglia; Mercè Gotsens; Oleguer Parés-Badell; María Teresa Brugal; Marta Torrens; Lara Treviño; Concepción Rodríguez-Díaz; José María Vázquez-Vázquez; Alicia Pascual; Marcela Coromina-Gimferrer; Míriam Jiménez-Dueñas; Israel Oliva; Erick González; Nicanor Mestre; Montse Bartroli
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.